What is happening with clinical trials in the UK as we slowly emerge from COVID-19, and how can you continue to support clinical research into new treatment options? The last year has seen intense focus on the development of treatments and vaccines for COVID-19, along with respiratory clinicians continuing toContinue Reading

On the 26th September 2021, our chairman Alan Wooler is to step down due to personal commitments. For those who are not aware, the majority of the Board of directors who run our charity also have day jobs.  Alan works in IT and has been with the same company forContinue Reading

The COVID-19 pandemic is a global emergency. Identifying populations who are at risk of severe complications is crucial in developing special measures to prevent or reduce severe illness and mortality in vulnerable patients. Emerging evidence indicates that alpha1-proteinase inhibitor might inhibit infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). α1-AntitrypsinContinue Reading

We were pleased to announce back in August 2020 that the first person was dosed with ZF874, a potential treatment for alpha-1-antitrypsin deficiency.  Then on the 24th September we published the details for HMR who are running the trail on behalf of Z Factor, asking for PiMZ people to help. Continue Reading

18th October 2020  Professor Gerry McElvaney (left), the study’s senior author and a consultant in Beaumont Hospital, and Professor Ger Curley (right) stand in front of the RCSI Education and Research Centre in Beaumont Hospital, Dublin.   Scientists have developed, for the first time, a score that can accurately predictContinue Reading